| scholarly article | Q13442814 |
| P50 | author | M Russo | Q53279337 |
| Paolo Vigneri | Q57012976 | ||
| Elena Tirrò | Q58204169 | ||
| Fiorenza Gianì | Q82695832 | ||
| P2093 | author name string | Chiara Romano | |
| Livia Manzella | |||
| Maria Stella Pennisi | |||
| Stefania Stella | |||
| Federica Martorana | |||
| Silvia Rita Vitale | |||
| Michele Massimino | |||
| Adriana Puma | |||
| Gianmarco Motta | |||
| Sandra Di Gregorio | |||
| P2860 | cites work | Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer | Q24300323 |
| Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer | Q24596266 | ||
| Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the ALK Gene | Q24598210 | ||
| Myeloid-derived suppressor cells: linking inflammation and cancer | Q24641811 | ||
| The first 30 years of p53: growing ever more complex | Q24645732 | ||
| Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives | Q26751274 | ||
| TERT promoter mutations in thyroid cancer | Q26770808 | ||
| Targeting RTK Signaling Pathways in Cancer | Q26781278 | ||
| Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer | Q27824825 | ||
| Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. | Q27851420 | ||
| Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer | Q27851560 | ||
| Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma | Q50961625 | ||
| Definition and management of radioactive iodine-refractory differentiated thyroid cancer | Q51090057 | ||
| Papillary Thyroid Carcinoma With Rare Exon 15 BRAF Mutation Has Indolent Behavior: A Single-Institution Experience. | Q51545085 | ||
| Oncogenic Signaling Pathways in The Cancer Genome Atlas | Q52602404 | ||
| Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers. | Q52609129 | ||
| The Immune Landscape of Cancer | Q52720878 | ||
| High-sensitivity BRAF mutation analysis: BRAF V600E is acquired early during tumor development but is heterogeneously distributed in a subset of papillary thyroid carcinomas. | Q53142928 | ||
| In papillary thyroid carcinoma, expression by immunohistochemistry of BRAF V600E, PD-L1, and PD-1 is closely related | Q53176123 | ||
| Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma | Q53471245 | ||
| The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study. | Q53835341 | ||
| Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors | Q54513531 | ||
| Management of treatment-related toxicities in advanced medullary thyroid cancer. | Q54980084 | ||
| Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. | Q55067769 | ||
| Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC | Q57591365 | ||
| Therapeutic advances in anaplastic thyroid cancer: a current perspective | Q57798697 | ||
| Whole-genome Sequencing of an Aggressive BRAF Wild-type Papillary Thyroid Cancer Identified EML4–ALK Translocation as a Therapeutic Target | Q58049946 | ||
| Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report | Q58101871 | ||
| Advances in small molecule therapy for treating metastatic thyroid cancer. | Q39364787 | ||
| New Insights in Thyroid Cancer and p53 Family Proteins. | Q39387810 | ||
| Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth | Q39472261 | ||
| Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas | Q39668456 | ||
| DeltaNp73alpha inhibits PTEN expression in thyroid cancer cells | Q39890321 | ||
| A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors | Q40173988 | ||
| Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer | Q40207526 | ||
| CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma | Q40247402 | ||
| Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. | Q40488053 | ||
| Prevalence and phenotypic correlations of EIF1AX mutations in thyroid nodules | Q40979072 | ||
| Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer | Q41091965 | ||
| Anaplastic lymphoma kinase L1198F and G1201E mutations identified in anaplastic thyroid cancer patients are not ligand-independent. | Q42315727 | ||
| A phase II study of imatinib in patients with advanced anaplastic thyroid cancer | Q42934129 | ||
| Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias. | Q43258298 | ||
| ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. | Q44106085 | ||
| Clinical significance of histone deacetylase (HDAC)-1, HDAC-2, HDAC-4, and HDAC-6 expression in human malignant and benign thyroid lesions. | Q44852149 | ||
| Somatostatin receptor expression in thyroid disease | Q45244510 | ||
| Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. | Q45998322 | ||
| Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers | Q46585245 | ||
| Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer | Q46636066 | ||
| Mammalian target of rapamycin is the key effector of phosphatidylinositol-3-OH-initiated proliferative signals in the thyroid follicular epithelium | Q46805123 | ||
| Targeted next-generation sequencing of cancer genes in poorly differentiated thyroid cancer. | Q47150624 | ||
| A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin | Q47160397 | ||
| Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer | Q47161687 | ||
| Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase II study | Q47208155 | ||
| Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial | Q47255118 | ||
| Molecular pathology of thyroid tumours of follicular cells: a review of genetic alterations and their clinicopathological relevance. | Q47295202 | ||
| Towards personalized, tumour-specific, therapeutic vaccines for cancer. | Q47789519 | ||
| Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial | Q47940756 | ||
| Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments | Q48075919 | ||
| PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma | Q48160811 | ||
| Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study. | Q48202591 | ||
| RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture | Q48334250 | ||
| Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence | Q48940023 | ||
| Targeted Therapy for Medullary Thyroid Cancer: A Review | Q49328959 | ||
| Refractory thyroid carcinoma: which systemic treatment to use? | Q49335901 | ||
| Altered Epigenetic Mechanisms in Thyroid Cancer Subtypes | Q49544932 | ||
| Gene fusions in thyroid cancer. | Q49549964 | ||
| Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia | Q49887884 | ||
| Remarkable Response to Crizotinib in Woman With Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma | Q50092862 | ||
| Predictive factors of outcome in poorly differentiated thyroid carcinomas | Q50137636 | ||
| Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. | Q27851702 | ||
| Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants | Q27853376 | ||
| Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial | Q27853396 | ||
| Pax-8-PPAR-γ fusion protein in thyroid carcinoma | Q28244806 | ||
| Integrated genomic characterization of papillary thyroid carcinoma | Q28251986 | ||
| Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results | Q28262507 | ||
| Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists | Q28269915 | ||
| Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications | Q28506804 | ||
| Identification of a recurrent STRN/ALK fusion in thyroid carcinomas | Q28539208 | ||
| BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis | Q29617585 | ||
| A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. | Q33569049 | ||
| TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer | Q33682388 | ||
| Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer | Q33710562 | ||
| The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors | Q33770769 | ||
| The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer | Q33770842 | ||
| Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling | Q33839230 | ||
| Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer | Q33849500 | ||
| Valproic acid, targets papillary thyroid cancer through inhibition of c-Met signalling pathway | Q33850376 | ||
| Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. | Q33995708 | ||
| ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. | Q34166741 | ||
| Cabozantinib in progressive medullary thyroid cancer | Q34185084 | ||
| TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas | Q34313648 | ||
| Molecular pathogenesis and mechanisms of thyroid cancer | Q34329018 | ||
| Patient-derived models of acquired resistance can identify effective drug combinations for cancer. | Q34447778 | ||
| Identification of oncogenic mutations and gene fusions in the follicular variant of papillary thyroid carcinoma. | Q34468149 | ||
| Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma | Q34468665 | ||
| NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States. | Q34509762 | ||
| BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas | Q34543110 | ||
| Targeting TRK family proteins in cancer | Q34550777 | ||
| Screening for Thyroid Cancer: US Preventive Services Task Force Recommendation Statement | Q34556507 | ||
| AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts | Q34563207 | ||
| Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity | Q34580980 | ||
| Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. | Q34608416 | ||
| Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer | Q37660065 | ||
| Calcium metabolism in health and disease | Q37678706 | ||
| Role of the wnt pathway in thyroid cancer | Q38014421 | ||
| The changing epidemiology of thyroid cancer: why is incidence increasing? | Q38259676 | ||
| The RET oncogene in papillary thyroid carcinoma | Q38366765 | ||
| Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary. | Q38461895 | ||
| A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer | Q38574759 | ||
| Ligands for the Nuclear Peroxisome Proliferator-Activated Receptor Gamma | Q38598888 | ||
| Entrectinib: a potent new TRK, ROS1, and ALK inhibitor | Q38604854 | ||
| Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer. | Q38702274 | ||
| A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma | Q38730197 | ||
| Combine and conquer: challenges for targeted therapy combinations in early phase trials. | Q38734451 | ||
| HDACs and HDAC Inhibitors in Cancer Development and Therapy | Q38947405 | ||
| A Brief Review on The Molecular Basis of Medullary Thyroid Carcinoma. | Q39064503 | ||
| Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models | Q39125714 | ||
| Heavy metals in the volcanic environment and thyroid cancer | Q39235822 | ||
| IRF5 promotes the proliferation of human thyroid cancer cells. | Q39364098 | ||
| Uncommon Mutation, but Common Amplifications, of thePIK3CAGene in Thyroid Tumors | Q58426250 | ||
| NTRK fusion-positive cancers and TRK inhibitor therapy | Q58547264 | ||
| Immune checkpoint inhibitors: recent progress and potential biomarkers | Q60302456 | ||
| The Emerging Role of Insulin Receptor Isoforms in Thyroid Cancer: Clinical Implications and New Perspectives | Q60923959 | ||
| Anaplastic lymphoma kinase fusions: Roles in cancer and therapeutic perspectives | Q61456293 | ||
| Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer | Q64066298 | ||
| Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models | Q64102893 | ||
| Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 | Q64226701 | ||
| Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study | Q64271812 | ||
| Effect of Combined Epigenetic Treatments and Ectopic NIS Expression on Undifferentiated Thyroid Cancer Cells | Q64376063 | ||
| Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer | Q68795478 | ||
| Thyroid carcinoma | Q72991392 | ||
| Specific pattern of RAS oncogene mutations in follicular thyroid tumors | Q73484426 | ||
| Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma | Q77357530 | ||
| Pathology and genetics of thyroid carcinoma | Q79387949 | ||
| Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer | Q79819385 | ||
| High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors | Q80140123 | ||
| A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma | Q80500352 | ||
| Phenotypical analysis of lymphocytes with suppressive and regulatory properties (Tregs) and NK cells in the papillary carcinoma of thyroid | Q83594322 | ||
| Regulatory T cells in cancer | Q84073243 | ||
| Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial | Q84862008 | ||
| Cabozantinib approved for advanced medullary thyroid cancer | Q85843286 | ||
| A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes | Q85954152 | ||
| Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial | Q88812861 | ||
| Thyroid cancer | Q89316166 | ||
| NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018 | Q90463312 | ||
| Pilot Dose Comparison of Apatinib in Chinese Patients With Progressive Radioiodine-Refractory Differentiated Thyroid Cancer | Q90570134 | ||
| Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid Cancer | Q90935719 | ||
| Cancer statistics, 2019 | Q90941571 | ||
| Activation of the IGF Axis in Thyroid Cancer: Implications for Tumorigenesis and Treatment | Q91588448 | ||
| PROGRAMMED CELL DEATH-LIGAND 1 OVEREXPRESSION IN THYROID CANCER | Q92626586 | ||
| Phase II Study of Daily Sunitinib in FDG-PET–Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation | Q34714310 | ||
| Motesanib diphosphate in progressive differentiated thyroid cancer. | Q34791480 | ||
| BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer | Q34919430 | ||
| Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. | Q34989774 | ||
| Rearrangements of NTRK1 gene in papillary thyroid carcinoma. | Q35010947 | ||
| Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. | Q35023367 | ||
| Uncommon GNAQ, MMP8, AKT3, EGFR, and PIK3R1 Mutations in Thyroid Cancers | Q35097324 | ||
| The Beneficial Effects of Valproic Acid in Thyroid Cancer Are Mediated through Promoting Redifferentiation and Reducing Stemness Level: An In Vitro Study | Q35194528 | ||
| Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial | Q35195766 | ||
| Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis | Q35746384 | ||
| Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer | Q35752400 | ||
| Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators | Q35868979 | ||
| Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial | Q35941777 | ||
| Molecular genetics of multiple endocrine neoplasia types 1 and 2. | Q36111935 | ||
| A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer | Q36201492 | ||
| A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study. | Q36311005 | ||
| Genetics of medullary thyroid cancer: An overview. | Q36372495 | ||
| Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. | Q36589374 | ||
| Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. | Q36618604 | ||
| A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment | Q36716739 | ||
| Sunitinib: from rational design to clinical efficacy | Q36747062 | ||
| Synergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer | Q36788057 | ||
| Retrospective Study of Sirolimus and Cyclophosphamide in Patients with Advanced Differentiated Thyroid Cancers | Q36798134 | ||
| Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. | Q36813603 | ||
| Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer | Q36822111 | ||
| Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study | Q36877022 | ||
| Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. | Q36877130 | ||
| Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial | Q36885846 | ||
| Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial | Q36910409 | ||
| Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. | Q36912949 | ||
| New developments in the diagnosis and treatment of thyroid cancer | Q37238757 | ||
| Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors | Q37311579 | ||
| Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years | Q37512001 | ||
| ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer | Q37627018 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 9 | |
| P921 | main subject | thyroid cancer | Q826522 |
| P577 | publication date | 2019-09-13 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Genes | Q5532699 |
| P1476 | title | Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice | |
| P478 | volume | 10 |
| Q98290370 | Appraisal of radioiodine refractory thyroid cancer: advances and challenges |
| Q132041414 | Single-Cell Analysis in the Omics Era: Technologies and Applications in Cancer |
| Q90192664 | TP53 Mutations in Serum Circulating Cell-Free Tumor DNA As Longitudinal Biomarker for High-Grade Serous Ovarian Cancer |
| Q89947291 | Targeting BCL-2 as a Therapeutic Strategy for Primary p210BCR-ABL1-positive B-ALL Cells |
| Q92704418 | Targeting Non-Oncogene Addiction: Focus on Thyroid Cancer |
Search more.